July 29, 2023
2 min watch
Save
VIDEO: Encapsulated cell therapy for macular telangiectasia advancing
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this Healio Video Perspective from OIS Retina, Richard Small previews a presentation that will cover phase 3 data on encapsulated cell therapy for the treatment of macular telangiectasia.
Two studies demonstrated statistical and clinical efficacy for the treatment of MacTel over 2 years, “but we also have data which actually shows that our technology and platform last much longer than 2 years,” he said.
Neurotech is preparing a license application for the FDA with the goal of having the platform on the market in 2024, according to Small.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Small reports being the CEO of Neurotech Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.